-
NewLink Genetics To Present Data On Cancer Immunotherapy Programs
5/16/2013
|
|
|
-
NewLink Genetics Posts Q1 Loss Per Share $0.33 Vs. Loss $0.23 Last Year
5/6/2013
|
-
NewLink Genetics To Present Preclinical Data On One Of Its IDO Pathway Inhibitors, NLG919
4/4/2013
|
-
NewLink Genetics Begins Phase 2 Trial Of IDO Pathway Inhibitor, Indoximod, For Metastatic Breast Cancer
4/2/2013
|
|
|
-
NewLink Genetics Q4 Net Loss $6.31 Mln Vs. Loss $5.81 Mln Prior Year
2/28/2013
|
|
|
|
|
|
|